Cargando…

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

BACKGROUND: Rituximab (R) in combination with DHAP is a widely accepted salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). A common adverse effect of this protocol is renal toxicity which may result in treatment discontinuation. Assuming that a lower sing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lisenko, K., McClanahan, F., Schöning, T., Schwarzbich, M. A., Cremer, M., Dittrich, T., Ho, A. D., Witzens-Harig, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828891/ https://www.ncbi.nlm.nih.gov/pubmed/27067641 http://dx.doi.org/10.1186/s12885-016-2289-y

Ejemplares similares

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial
por: Witzens-Harig, Mathias, et al.
Publicado: (2013)

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma
por: Lisenko, K., et al.
Publicado: (2017)

The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial
por: Witzens-Harig, Mathias, et al.
Publicado: (2021)

Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma
por: Devi, Kanta, et al.
Publicado: (2023)

Unusually swift response of relapsed Burkitt leukemia to R‐DHAP
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial
por: Witzens-Harig, Mathias, et al.
Publicado: (2011)

Physiological effects of autotoxicity due to DHAP stress on Picea schrenkiana regeneration
por: Yang, Li, et al.
Publicado: (2017)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
por: Vacirca, Jeffrey L., et al.
Publicado: (2013)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

Enhanced MALDI-TOF MS Analysis of Phosphopeptides Using an Optimized DHAP/DAHC Matrix
por: Hou, Junjie, et al.
Publicado: (2010)

Temozolomide and cisplatin in relapsed/refractory acute leukemia
por: Seiter, Karen, et al.
Publicado: (2009)

The efficacy of rituximab in adult frequently relapsing minimal change disease
por: King, Catherine, et al.
Publicado: (2017)

Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
por: Hess, Georg, et al.
Publicado: (2020)

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
por: Murayama, Kayoko, et al.
Publicado: (2022)

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease
por: Papakrivopoulou, Eugenia, et al.
Publicado: (2016)

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting
por: Lisenko, Katharina, et al.
Publicado: (2017)

Efficacy of low-dose rituximab in minimal change disease and prevention of relapse
por: Zhang, Jian, et al.
Publicado: (2023)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
por: Zhang, Peng‐Fei, et al.
Publicado: (2020)

Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
por: Thiel, Jens, et al.
Publicado: (2013)

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma
por: Timmerman, John, et al.
Publicado: (2020)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

Report of Two Cases of Typhoid Fever
por: McClanahan, J. M.
Publicado: (1899)

Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis
por: Ren, Hong, et al.
Publicado: (2017)

Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease
por: Benedetti, Edoardo, et al.
Publicado: (2023)

The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin’s lymphoma who are candidates for up-front autologous stem cell transplantation
por: Jeon, So Yeon, et al.
Publicado: (2018)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
por: Leonard, John P., et al.
Publicado: (2019)

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
por: de Vos, S, et al.
Publicado: (2018)

Phase II study of dose‐adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B‐cell lymphoma patients
por: Yamasaki, Satoshi, et al.
Publicado: (2020)

Cd20 Expression and Effects on Outcome of Relapsed/Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab
por: Rasheed, Afshan Asghar, et al.
Publicado: (2018)

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma
por: Terui, Yasuhito, et al.
Publicado: (2021)

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Zhang, Xiyuan, et al.
Publicado: (2023)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Toxicity Minimized Cryoprotectant Addition and Removal Procedures for Adherent Endothelial Cells
por: Davidson, Allyson Fry, et al.
Publicado: (2015)

Efficacy and Safety of Rituximab for Refractory and Relapsing Thrombotic Thrombocytopenic Purpura: A Cohort of 10 Cases
por: Omri, Halima El, et al.
Publicado: (2015)

Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement
por: Lehners, Nicola, et al.
Publicado: (2017)

Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
por: Kim, Ki-Hyang, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_lssfdtisi717141bnpj0ev5ckq